Laden…
[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
Psilocybin is a psychoactive alkaloid found in certain species of mushrooms and is known for its hallucinogenic properties. It is often studied in the psychonautical community and in research on mental disorders.
Class
Psychedelika
Pharmacological context
Mechanism
Psilocybin primarily acts by binding to serotonin receptors in the...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Moderate Risk
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Frequently checked combinations
Psilocybin primarily acts by binding to serotonin receptors in the brain, particularly the 5-HT2A receptors, leading to altered perceptions and states of consciousness.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 10–20 mg
Total duration 4–6 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 1–2 mg |
| Reported | 10–20 mg |
| Strong | 20–30 mg |
Oral
Onset
20–40 minutes
Peak
1–2 hours
Total duration
4–6 hours
After effects
2–6 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Evidence
strong
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Aggregated signals from 11 experience reports on Psilocybin.
Community data from 11 reports. Not a scientific assessment.
All reports →Experiences + discussions about Psilocybin
No community discussions about Psilocybin yet. Start the first evidence-based discussion and share your experiences.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.